|
15 Nov 2019 |
Qtrilmet approved in the EU for the treatment of type-2 diabetes
|
|
15 Nov 2019 |
U.S. FDA Grants BeiGene’s BRUKINSA™ (zanubrutinib) Accelerated Approval to Treat Adult Patients with Mantle Cell Lymphoma Who Received at Least One Prior Therapy
|
|
15 Nov 2019 |
Oncternal Therapeutics Announces Presentation of Interim Clinical Data on TK216, its First-in-class, Targeted ETS Inhibitor, in Patients with Relapsed or Refractory Ewing Sarcoma at the CTOS 2019 Annual Meeting
|
|
15 Nov 2019 |
FETROJA® (cefiderocol) Approved by the FDA for Treatment of Complicated Urinary Tract Infections (cUTI) in Adult Patients with Limited or No Alternative Treatment Options
|
|
14 Nov 2019 |
VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder
|
|
14 Nov 2019 |
US FDA accepts regulatory submission for selumetinib in neurofibromatosis type 1 and grants Priority Review
|
|
13 Nov 2019 |
Therapix Biosciences Announces Positive Topline Results From Phase IIa Clinical Trial of THX-110 for Obstructive Sleep Apnea Program
|
|
13 Nov 2019 |
EpicentRx Closes $35 million Series D Financing to Support Development of Small Molecule Immunotherapy and Oncolytic Viral Platform
|
|
13 Nov 2019 |
Aravive and AstraZeneca Announce Initiation of Randomized Phase 1/2 Study of AVB-500 in Combination with Durvalumab in Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer
|
|
13 Nov 2019 |
Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients
|
|
13 Nov 2019 |
Moleculin Announces FDA Approval of IND for its STAT3 Inhibitor in Emory University Clinical Trial
|
|
13 Nov 2019 |
Actelion Withdraws Regulatory Filings to Extend the Indication of OPSUMIT® (macitentan 10mg) in CTEPH
|
|
13 Nov 2019 |
DURECT Corporation Announces Positive Results from the Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis Patients in a Late-Breaking Presentation at The Liver Meeting
|
|
13 Nov 2019 |
X4 Pharmaceuticals Receives Breakthrough Therapy Designation from the FDA for Mavorixafor for the Treatment of WHIM Syndrome
|
|
13 Nov 2019 |
Boehringer Ingelheim and Lilly initiate first ever study to assess empagliflozin in people hospitalised for acute heart failure who have been stabilised
|
|
12 Nov 2019 |
Kadmon Announces that KD025 Met Primary Endpoint at Interim Analysis of Pivotal Trial in Chronic Graft-Versus-Host Disease
|
|
12 Nov 2019 |
Hua Medicine’s Pivotal Phase III Monotherapy Trial of Dorzagliatin, a Dual-Acting Glucokinase Modulator, Achieves Primary Efficacy Endpoint in Patients with Type 2 Diabetes
|
|
12 Nov 2019 |
Supernus Submits New Drug Application for SPN-812 for the Treatment of ADHD
|
|
12 Nov 2019 |
Kezar Announces Promising New Data with KZR-616 at the American College of Rheumatology Annual Meeting
|
|
12 Nov 2019 |
Aptinyx Initiates Two Phase 2 Studies of NYX-2925 in Patients with Chronic Centralized Pain Conditions
|
|
12 Nov 2019 |
Poxel Announces Presentation of PXL065 Phase 1a Results at the Liver Meeting® 2019
|
|
12 Nov 2019 |
Pfizer Announces Results of Phase 3 Study for XELJANZ® (tofacitinib) in Juvenile Idiopathic Arthritis Ahead of Presentation at 2019 American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting
|
|
12 Nov 2019 |
Gossamer Bio Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combination With KEYTRUDA® (Pembrolizumab) in Selected Advanced Solid Tumors
|
|
12 Nov 2019 |
Reata Announces Positive Topline Year One Results From Pivotal Phase 3 Cardinal Study of Bardoxolone Methyl in Patients With Alport Syndrome
|
|
12 Nov 2019 |
Novartis data show tropifexor (LJN452) significantly improves several key biomarkers of NASH in patients with moderate to severe fibrosis
|
